Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—A systematic enquiry and overview

Varma, Rajesh; Sinha, Deepali; Gupta, Janesh

doi:10.1016/j.ejogrb.2005.10.029

Cited by 123 publications

(75 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The LNG IUS has been approved for contraception and heavy menstrual bleeding therapy in Latvia since 1998. The use of the LNG IUS is increasing, particularly in the treatment of endometriosis, endometrial hyperplasia (8). Since 2006 the LNG IUS has been included in the list of reimbursable drugs in Latvia with the indication N92 -excessive, frequent and irregular menstruation ( ICD-10).…”

Section: Introductionmentioning

confidence: 99%

The Influence of the Levonorgestrel-Releassing Intrauterine System (Lng Ius) on Metabolic Markers in Women with Normal Body Mass and Overweight Women

Vasaraudze¹,

Rezeberga

Erts

et al. 2013

Acta Chirurgica Latviensis

View full text Add to dashboard Cite

27Summary Introduction. In Latvia, the number of overweight women is increasing, while the rate of cardio vascular disease (CVD) is one of the highest in the European Union. The influence of hormonal contraception on the development of CVD has not been studied in Latvia so far. Aim of the study. A nonrandomized open-label prospective trial of healthy reproductive-age women desiring to use the LNG IUS. Materials and methods. Before starting the use of contraception and six months after starting the use of contraception, the homeostasis model assessment insulin resistant (HOMA-IR) score, insulin sensitivity (HOMA-%S) and β-cell function (HOMA-%B) were calculated using fasting glucose (FG) and C peptide values. There were also determined other cardio-metabolic parameters: total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride level, systolic and diastolic blood pressure, and abdominal circumference. Results. Thirty women were involved in the study: seventeen women with a normal body-mass index (BMI) (BMI below 25) and thirteen overweight women (BMI above 25). When using the LNG IUS, the fasting glucose level increased in women with normal body mass, the level of insulin sensitivity decreased in both study groups; C peptide level, β-cell function and insulin resistance increased in both groups, but the changes were not statistically reliable (p>0.05). Conclusion. Although during the study there were determined changes in the FG level, insulin sensitivity, C peptide, β-cell function and insulin resistance parameters, these changes are not clinically significant, and the LNG IUS may be safely used clinically both by women with normal body mass and overweight women. Keywords: Levonorgestrel-releasing intrauterine system, contraception, body mass index, insulin resistance, fasting glucose. ORIGINAL ARTICLEThe Influence of the Levonorgestrel-Releassing Intrauterine System (Lng Ius) on Metabolic Markers in Women with Normal Body Mass and Overweight Women Ineta Vasaraudze*,**, Dace Rezeberga**,***, Renars Erts**, Aivars Lejnieks**,*** *I.Vasaraudze Private Clinic Ltd, Riga, Latvia **Riga Stradins University, Latvia ***Riga East Clinical University Hospital, Riga, Latvia to women like gestational diabetes, pregnancy-inducted hypertension & preeclampsia, polycystic ovarian syndrome (6). Since pregnancy-related complications are more common among obese women than among women with normal body weight, the choice of a safe long-term contraception method is of extreme importance. Long-acting reversible contraceptive methods (LARC) include: the copper containing intrauterine device (IUD), the etonogestrel containing sub-dermal implant (not available in Latvia yet) and the levonorgestrelreleasing intrauterine system (LNG IUS). Both methods available in Latvia are long acting (5-12 years), very effective (Perl index is 0.8 and 0.2 for the typical use in one year, respectively), and there is no evidence of a delay in the return of fertility following the removal of IUDs or LNG IUS.A...

show abstract

Section: Introductionmentioning

confidence: 99%

The Influence of the Levonorgestrel-Releassing Intrauterine System (Lng Ius) on Metabolic Markers in Women with Normal Body Mass and Overweight Women

Vasaraudze¹,

Rezeberga

Erts

et al. 2013

Acta Chirurgica Latviensis

View full text Add to dashboard Cite

show abstract

“…12,17 To the best of our knowledge, our study is the first to compare the endometrial effects of low dose estradiol (1 mg/day, p.o.) associated with LNG-IUS.…”

Section: Discussionmentioning

confidence: 99%

“…It releases 20 µg/day of levonorgestrel, with low systemic absorption, when compared to oral administration. 17 There are few prospective studies evaluating LNG-IUS use in HT, always associated with conventional estrogen doses. [18][19][20] Drospirenone (DRSP) is a synthetic, spironolactone-derived progestogen with a pharmacological profile that closely mimics that of endogenous progesterone.…”

Section: Introductionmentioning

confidence: 99%

Effects of hormone therapy on the endometrium in postmenopausal women: a one year randomized trial of low dose oral estradiol in association with a levonorgestrel-releasing intrauterine system or drospirenone

Schvartzman

Magalhães

Freitas

et al. 2013

Rev. Bras. Saude Mater. Infant.

View full text Add to dashboard Cite

Effects of hormone therapy on the endometrium in postmenopausal women: a one year randomized trial of low dose oral estradiol in association with a levonorgestrel-releasing intrauterine system or drospirenone Efeitos da terapia hormonal no endométrio de mulheres na pós-menopausa: estudo clínico randomizado por um ano com estradiol oral em baixa dosagem em associação com sistema intrauterino com levonorgestrel ou drospirona Resumo Objetivos: comparar os efeitos endometriais e no padrão de sangramento uterino de tratamento com (1) sistema intrauterine com levonorgestrel (SIU-LNG) e estradiol (1 mg/dia, v.o.) ou (2) associação oral de drospirenona (DRSP) (2 mg/dia) e estradiol (1 mg/dia).Métodos the safety and efficacy of continuous combined oral HT with 1 mg 17 β-estradiol (E2) plus 2 mg DRSP for the treatment of climacteric symptoms 21,[23][24][25] This association has anti-androgenic and anti-aldosterone properties. 22,23 The present study was designed to assess the endometrial effects (bleeding patterns, endometrial thickness, hysteroscopic pattern, and endometrial histology) in postmenopausal women using lowdose estradiol associated with either LNG-IUS or oral drospirenone.

show abstract

“…Some patients may even be amenorrheic. Studies have shown that women who use LNG-IUD experience decrease in blood loss and increase in hemoglobin levels 1,2 . We often use LNG-IUD to treat abnormal uterine bleeding in our unit.…”

Section: Abnormal Uterine Bleeding Is a Common Cause For Visits To Gymentioning

confidence: 99%

Levonorgestrel containing intrauterine device (Mirena®) in the treatment of dyfunctional uterine bleeding; patients’ view and our experience

Balcı¹,

Hocaoğlu²,

Göynümer³

et al. 2016

MMJ

View full text Add to dashboard Cite

ıntroductıonAbnormal uterine bleeding is a common cause for clinic visits of women of reproductive age. Once menopause sets in, it resolves. Therefore, many women need treatment during premenopausal years. Dysfunctional abnormal uterine bleeding is treated with hormonal / non-hormonal medications and with surgery. Hormonal treatment modalities include oral contraceptive pills, oral gestagens, levonorgestrel-

show abstract

Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—A systematic enquiry and overview

Cited by 123 publications

References 109 publications

The Influence of the Levonorgestrel-Releassing Intrauterine System (Lng Ius) on Metabolic Markers in Women with Normal Body Mass and Overweight Women

The Influence of the Levonorgestrel-Releassing Intrauterine System (Lng Ius) on Metabolic Markers in Women with Normal Body Mass and Overweight Women

Effects of hormone therapy on the endometrium in postmenopausal women: a one year randomized trial of low dose oral estradiol in association with a levonorgestrel-releasing intrauterine system or drospirenone

Levonorgestrel containing intrauterine device (Mirena®) in the treatment of dyfunctional uterine bleeding; patients’ view and our experience

Contact Info

Product

Resources

About